Next-Gen Cancer Detection
We're developing blood tests to improve the reliability and affordability of cancer detection
Next-Gen Cancer Detection
We're developing blood tests to improve the reliability and affordability of cancer detection
We're developing blood tests to improve the reliability and affordability of cancer detection
We're developing blood tests to improve the reliability and affordability of cancer detection
At Definitive Diagnostics, our mission is to target large and expensive gaps in cancer care by improving the reliability and
affordability of cancer detection for millions of patients. Our goal is to accelerate timely diagnosis and eliminate unnecessary waste from false test results.
Definitive Diagnostics utilizes a patented, protein-based method that measures discovered biomarker patterns to detect cancer at its earliest stage. In early testing, we've detected cancer as early as Stage 0 in breast cancer and at Stage I in lung, colorectal, ovarian, and pancreatic cancers.
We're merging our protein platform with AI to enhance performance of our pattern detection technology while preparing for future discovery into other cancers and subtypes. As we expand our patient data pool, our technology will allow us to discover new patterns to expand and speed diagnosis for millions of early stage patients.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.